Navigation Links
Savient Pharmaceuticals Announces Search for CEO

EAST BRUNSWICK, N.J., Dec. 28, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its Board of Directors has initiated a search for a Chief Executive Officer.  Paul Hamelin, Savient's President since November 2008 and its most senior executive officer, will continue to lead the day-to-day operations of the company until Savient hires a CEO.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.


Any statements contained in this release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements regarding the search for a chief executive officer and the continuing role of Paul Hamelin are forward-looking statements.  All forward-looking statements rely on assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Important factors that may affect our ability to achieve the matters discussed in these forward-looking statements include our ability to successfully identify a person to serve as chief executive officer, our ability to negotiate an employment agreement with any such person, and other important factors set forth in our filings with the Securities and Exchange Commission. Savient assumes no obligation to update any forward-looking statements.


SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
4. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
5. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
6. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
7. Savient Pharmaceuticals To Hold First Quarter 2010 Results
8. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
11. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015  EndoChoice Holdings, Inc. (NYSE:  GI) ... 2015 financial results on Thursday, November 5, 2015 before ... --> . --> ... 5, 2015 at 9:00 a.m. ET to discuss the ... callers and (412) 317-5469 for international callers. A live ...
(Date:10/13/2015)... SAN DIEGO , October 13, 2015 ... RGBP) today announced the appointment of Harry Lander , ... with the Company,s Chairman & CEO David Koos ... in small molecule and immuno-oncological therapeutics. --> ... announced the appointment of Harry Lander , PhD as ...
(Date:10/13/2015)... , Oct. 13, 2015 China Jo-Jo ... " China Jo-Jo "), a leading China-based retail, wholesale ... through its own online and retail pharmacies, announced preliminary ... official branded online pharmacy through , growing ... a record 25%. China Jo-Jo,s ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... celebrating the opening of the Integrative Biosciences Center (IBio), a $93 million facility ... A grand opening celebration will be held at 10:30 a.m. Wednesday, Oct. 14, ...
(Date:10/13/2015)... ... October 14, 2015 , ... The ... of needle-placement technique in radiofrequency ablation for treatment of lumbar facet arthropathy ”. ... in nature, highlights the importance of anatomically correct needle placement technique for lumbar ...
(Date:10/13/2015)... ... October 13, 2015 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... A Commitment to Cure last night at the Mandarin Oriental in New York ...
(Date:10/13/2015)... ... 13, 2015 , ... “Women have 2 questions when they find out they ... second is, “Will I lose my hair?’” , Carly Klein is the Founder of ... medical professionals to develop personalized hair loss treatment plans. With 10 years’ experience in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Though trick-or-treating remains ... confines of their home. Whether it's making fun pre or post trick-or-treat snacks ... Florida Dairy Farmers. , Recipe 1: Green Chile Queso Dip with Sriacha ...
Breaking Medicine News(10 mins):